Loading...
Market
In which major markets will PTC's AADC gene therapy be available by end of 2025?
2
Resolution / Starting Odds
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
Press releases from PTC Therapeutics and regulatory agencies
Story
FDA Approves PTC Therapeutics' Gene Therapy for AADC Deficiency
Nov 13, 2024, 11:18 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy is administered directly in the brain, marking a significant advancement in the treatment of neurological conditions. The approval has positively impacted PTC Therapeutics' stock, which saw a 2% increase in aftermarket trading.
View original story
Similar markets
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%